Antibacterial Therapy and Newer Agents , An Issue of Medical Clinics of North America, 1st Edition
Authors :
Keith S. Kaye & Donald Kaye
This issue of Medical Clinics of North America brings the physician up to date on the newest agents for antibacterial therapy. New drugs are covered, as well as new approaches. Topics include the newer fluoroquinolones; epidemiology, mole ...view more
This issue of Medical Clinics of North America brings the physician up to date on the newest agents for antibacterial therapy. New drugs are covered, as well as new approaches. Topics include the newer fluoroquinolones; epidemiology, molecular mechanisms, and clinical management of pathogens resistant to antibacterial agents; current use for old antibacterial agents, including polymyxins, rifamycins, and aminoglycosides; topical antibacterial agents; newer beta-lactam antibiotics, including doripenem, ceftobiprole. ceftaroline, and cefepim; the use of antibacterial agents in renal failure; antibiotics for gram positive bacterial infections, including vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinolones, daptomycin, telavancin, and ceftaroline; as well as macrolides, ketolides, and glycylcyclines, including azithromycin, clarithromycin, telithromycin, and tigecycline.
This issue of Medical Clinics of North America brings the physician up to date on the newest agents for antibacterial therapy. New drugs are covered, as well as new approaches. Topics include the newer fluoroquinolones; epidemiology, molecular mechanisms, and clinical management of pathogens resistant to antibacterial agents; current use for old antibacterial agents, including polymyxins, rifamycins, and aminoglycosides; topical antibacterial agents; newer beta-lactam antibiotics, including doripenem, ceftobiprole. ceftaroline, and cefepim; the use of antibacterial agents in renal failure; antibiotics for gram positive bacterial infections, including vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinolones, daptomycin, telavancin, and ceftaroline; as well as macrolides, ketolides, and glycylcyclines, including azithromycin, clarithromycin, telithromycin, and tigecycline.
Author Information
By Keith S. Kaye, MD, MPH, Professor of Internal Medicine and Infectious Diseases
Wayne State University School of Medicine
Corporate Director of Infection Prevention
Hospital Epidemiology and Antimicrobial Stewardship
Detroit Medical Center
Detroit, MI and Donald Kaye, MD, MACP
https://www.us.elsevierhealth.com/antibacterial-therapy-and-newer-agents-an-issue-of-medical-clinics-of-north-america-9781455722914.html6715Antibacterial Therapy and Newer Agents , An Issue of Medical Clinics of North Americahttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9781455722914.jpg58.0982.99USDInStock/Medicine/Internal Medicine/Clinics/Clinics194388725525504113841826925145120This issue of Medical Clinics of North America brings the physician up to date on the newest agents for antibacterial therapy. New drugs are covered, as well as new approaches. Topics include the newer fluoroquinolones; epidemiology, molecular mechanisms, and clinical management of pathogens resistant to antibacterial agents; current use for old antibacterial agents, including polymyxins, rifamycins, and aminoglycosides; topical antibacterial agents; newer beta-lactam antibiotics, including doripenem, ceftobiprole. ceftaroline, and cefepim; the use of antibacterial agents in renal failure; antibiotics for gram positive bacterial infections, including vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinolones, daptomycin, telavancin, and ceftaroline; as well as macrolides, ketolides, and glycylcyclines, including azithromycin, clarithromycin, telithromycin, and tigecycline. This issue of Medical Clinics of North America brings the physician up to date on the newest agents for antibacterial therapy. New drugs are covered, as well as new approaches. Topics include the newer fluoroquinolones; epidemiology, molecular mechanisms, and clinical management of pathogens resistant to antibacterial agents; current use for old antibacterial agents, including polymyxins, rifamycins, and aminoglycosides; topical antibacterial agents; newer beta-lactam antibiotics, including doripenem, ceftobiprole. ceftaroline, and cefepim; the use of antibacterial agents in renal failure; antibiotics for gram positive bacterial infections, including vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinolones, daptomycin, telavancin, and ceftaroline; as well as macrolides, ketolides, and glycylcyclines, including azithromycin, clarithromycin, telithromycin, and tigecycline.00add-to-cart97814557229142011 and earlierProfessionalBy Keith S. Kaye, MD, MPH and Donald Kaye, MD, MACP20111Book152w x 229h (6.00" x 9.00")Saunders224Jul 7, 2011IN STOCK - This may take up to 5 business days to shipBy <STRONG>Keith S. Kaye</STRONG>, MD, MPH, Professor of Internal Medicine and Infectious Diseases
Wayne State University School of Medicine
Corporate Director of Infection Prevention
Hospital Epidemiology and Antimicrobial Stewardship
Detroit Medical Center
Detroit, MI and <STRONG>Donald Kaye</STRONG>, MD, MACPClinicsClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select